Search global stocks & ETFs...Ctrl K
Learn Mode
Beam Therapeutics IncBEAM
$34.79
$1.31 (3.913%)
$34.86
$0.07 (0.201%)
BEAM
Stock Profile
08-03
Recommended Metric
Score Card
Explore Scores Tab
2.35
Bad
Valuation Score
Key Score
3.00
Average
Management
3.00
Average
Growth
4.00
Good
Profitability
2.00
Bad
Fin. Health
2.00
Bad
Dividends
--
--
Analyst
2.00
Bad
Insider Transactions
Explore Insider Tab ›Buy Transactions
Sell Transactions
Peers
Select stocks to compare
Price Targets & Ratings
View Analysis
1-year price targets, ending May 11, 2027
Current
$34.79
Baseline
High
$84.00
▲
141.45%
Avg
$51.02
▲
46.66%
Low
$26.26
▼
-24.52%
Analyst Ratings based on 25 Analysts
Strong Buy
1144%
Buy
1144%
Hold
312%
Sell
000%
Strong Sell
000%
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 511 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).Read More